All News
A higher number of axSpA pts enrolled in BE MOBILE 1&2 who were treated with BKZ achieved remission accdg to the OSI vs. ASDAS ID (40.5% vs 15.2%) at wk 16 until wk 52.
OSI a better measure of remission?
@RheumNow #ACR24 abs2362 https://t.co/GCHjXQi9S9
sheila RHEUMarampa ( View Tweet)
Dr @ZahiTouma discusses the attribution rules for the NPSLE syndromes
Attribute to #SLE if
- onset of NP is near the SLE dx
- absence of concurrent nonSLE factors
- ⬇️ frequency of NP events in the gen pop'n
- diagnostic tools favor NPSLE
@RheumNow #ACR24 https://t.co/e1xBK4Xzsw
sheila RHEUMarampa ( View Tweet)
Very informative slide describing the 2 NPSLE pathogenetic pathways & their differences in mediators, mechanisms and NP events.
@RheumNow #ACR24
@rheumarhyme @theactiverheum https://t.co/D3XFDqxMBq
sheila RHEUMarampa ( View Tweet)
Walsh et al. Direct mailing of PEST questionnaire to psoriasis patients. 13% PEST+, 4% seen by rheum (to date). 75% deemed appropriate for rheum to see - breakdown in picture. @RheumNow #ACR24 Abstr#2635 https://t.co/vlGJ977SV7 https://t.co/dbDUpwDZxy
Links:
Richard Conway RichardPAConway ( View Tweet)
Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf
Links:
Richard Conway RichardPAConway ( View Tweet)
Medeiros-Ribeiro et al. Holding MTX for 2 weeks after recombinant zoster vaccine increases response with no increase in flare. @RheumNow #ACR24 Abstr#2612 https://t.co/NEop0XB5Ak https://t.co/P4S2qzbkTs
Links:
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis.All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
How Online Searches Reveal Patient Needs
In the digital age, managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. #ACR24
https://t.co/AbHGNAsIpH https://t.co/nuoQeigJfE
Dr. John Cush RheumNow ( View Tweet)
Disease specific chatbots might be primetime - investigators from NYC made the a #LupusCoach chatbot - patients indicated high levels of satisfaction and were excited about it.
@rheumnow abst#2160 #ACR24
Bella Mehta bella_mehta ( View Tweet)
A#2291
ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens
Symptomatology is complex in SjD and beyond traditional disease activity markers
@RheumNow #ACR24 https://t.co/AhstAFjOVS
Eric Dein ericdeinmd ( View Tweet)
Abstract 1925: Caution w/ ADI as proxy for neighborhood disadvantage
- ↑ ADI didn’t correlate with ER visits or hospitalizations, but ↓ Childhood Opportunity Index (COI) did:
ER visits: aOR 2.85 (95%CI 1.12-7.26)
Hospitalizations: aOR 4.15 (95%CI 1.25-13.81)
@RheumNow #ACR24 https://t.co/dVZi8oqBnI
Akhil Sood MD AkhilSoodMD ( View Tweet)
Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephritis @RheumNow #ACR24 https://t.co/rz9AhPS2cl
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Long COVID outcomes in Autoimmune diseases (AID)
Abstract 1897:
- Long COVID symptoms higher among AID pts vs controls
- vaccinated may have protective benefit
@RheumNow #ACR24 https://t.co/2SEcbkxfcU
Links:
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract 1915: Barriers to repro health discussions in rheumatology clinic
- Spanish speaking & IA patients report language differences + OB/GYN deferrals as barriers
Appointment time, clinician knowledge, or patient comfort did not make a difference
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract 1842: Off the shelf CAR T therapy
No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Applying the guidelines to Cases- Dr M Dall’Era for a pt wit extrarenal lupus and active LN. #ACR24 @rheumnow https://t.co/lvOUWjEdEz
Links:
TheDaoIndex KDAO2011 ( View Tweet)
The updated 2024 ACR Guideline for Dx and Tx of #lupus nephritis is here!
Dr. Lisa Samaritano discusses the key recommendations 👇
For all pts: screen for LN, give HCQ and RAAS for pts with ⬆️ proteinuria
GCs in pts w/ LN class III/IV &/or V.
@Rheumnow #ACR24 @rheumarhyme https://t.co/wLVRGktR59
Links:
sheila RHEUMarampa ( View Tweet)
The overview for #lupus nephritis tx.
Triple therapy is preferred as first line due to:
1. RCTs (BLISS-LN & AURORA 1) showing improved outcomes w/ triple txs
2. Nephron loss happens with ongoing LN - time is kidney!
@RheumNow #ACR24 https://t.co/IQo3q3O1pt
Links:
sheila RHEUMarampa ( View Tweet)
Overall very reasonable, aligning ACR recs w/other guidance groups & updated data
Remember: guidelines are meant to be broken. Some patients can likely avoid pulse, others may need more steroid on the back end, biopsies are not benign
#ACR24 @RheumNow
Mike Putman EBRheum ( View Tweet)
Happening now, new guidelines for mgmt. A few highlights:
Recommend prompt GC therapy, pulse x1-3d followed by oral pred (<0.5mg/kg/d) w/taper to <5mg by 6 months
Aligns with EULAR recs for a much-lower dose than most clinicians currently doing
#ACR24 @RheumNow https://t.co/B71i7FBYlQ
Mike Putman EBRheum ( View Tweet)
